Save with generic and brand Cabometyx today.
Click here for information on Cipla generics (Immediate availability)
For Brand Cabomeytx, Non-english packaging is often present for European medicines- English label and English insert included. Plan in advance - allow us 7 days to ship this brand name medicine.
According to the European Medicines Agency, brand name Cabometyx originating from Europe is manufactured at the following site(s):Patheon France 40 Boulevard de Champaret 38300 Bourgoin Jallieu, FranceTjoapack Netherlands B.V. Nieuwe Donk 9 4879 AC Etten-Leur The NetherlandsRottendorf Pharma GmbH Ostenfelderstrasse 51 – 61 D-59320 Ennigerloh, Germany
Information about Cabometyx (Cabozantinib)
CABOMETYX (cabozantinib) is an effective treatment option for advanced renal cell carcinoma (RCC), addressing both initial and subsequent therapeutic needs. It is indicated as a monotherapy for adult patients with advanced RCC, particularly for those who are either treatment-naïve and classified as having intermediate or poor risk, or for those who have previously undergone treatment with vascular endothelial growth factor (VEGF) targeted therapy.
Additionally, CABOMETYX can be used in combination with nivolumab as a first-line treatment for advanced RCC. This combination approach provides a potent therapeutic strategy by leveraging the synergistic effects of both medications to improve treatment outcomes and manage the disease more effectively.
Product Highlights
- Used for the treatment of advanced renal cell carcinoma (RCC), hepatocellular carcinoma (HCC) in patients who have previously received sorafenib, and progressive, well-differentiated thyroid cancer (DTC) in adults who have been treated with prior therapy.
- Cabozantinib inhibits several receptor tyrosine kinases involved in cancer progression, including MET, VEGFR, and AXL, which helps to inhibit tumor growth and metastasis.
Key Ingredient
Key Benefits
- Demonstrated effectiveness in shrinking tumors and slowing disease progression in various cancers.
- Specifically targets multiple pathways involved in tumor growth and angiogenesis (the formation of new blood vessels).
- Approved for use in multiple cancer types, including RCC, HCC, and DTC.
Direction of Use
- The dosage of Cabometyx is typically 60 mg taken orally once daily.
- It should be taken on an empty stomach, either at least 2 hour before or 1 hour after food.
- The treatment duration depends on the patient's response and tolerance, as determined by their healthcare provider.
Safety Concerns
- Fatigue, nausea, diarrhea, decreased appetite, and weight loss.
- Liver problems, gastrointestinal perforation, bleeding events, hypertension, and possible thyroid problems.
- Regular monitoring of liver function tests, blood pressure, and other parameters is necessary to manage potential side effects.
Avoid Cabometyx If
- It should be avoided during pregnancy due to potential harm to the unborn baby. Women of childbearing age should use effective contraception during treatment.
- If you have a known allergy to cabozantinib or any of the other components in the medication.
- Not recommended for patients with severe liver impairment as it may increase the risk of severe side effects.
